Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.
Advertisement Those interested in taking part in clinical trials for HIV prevention – including the REV UP clinical trial – can contact Sherri Karas Certo by calling or texting 412-818-4942 or ...
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to ...
A new study has found that a twice-yearly injection of lenacapavir can reduce the risk of HIV by 96%.
A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...
FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...
Rwanda is set to roll out the long-acting injectable PrEP known as cabotegravir (CAB-LA). PrEP refers to the use of ...
Courtney Breen, an analyst from Bernstein, has initiated a new Buy rating on Gilead Sciences (GILD).Don't Miss our Black Friday Offers:Unlock ...
The US President's Emergency Plan for AIDS Relief (PEPFAR), the largest global health investment ever by any country to ...
Twice-yearly injectables might soon be available to help prevent HIV infection. The injectable Sunlenca is even more ...
A twice-yearly shot could end AIDS, but will it reach everyone who needs it? Gilead's HIV prevention drug is 100% effective ...